会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • Polycarbonates containing low levels of methyl salicylate prepared by a melt polymerization in a reactive extruder
    • 含有低水平的水杨酸甲酯的聚碳酸酯通过在反应性挤出机中的熔融聚合制备
    • US07485695B2
    • 2009-02-03
    • US11470333
    • 2006-09-06
    • Peter DavisHans Looij
    • Peter DavisHans Looij
    • C08G64/00C08G63/02
    • C08G64/205B29C47/0004B29C47/0009B29C47/0021B29C47/0871B29C47/38B29C47/6025B29C47/6031B29C47/6056B29C47/76B29C47/767B29K2069/00C08G64/307
    • Polycarbonate is prepared by reactive extrusion on a reactive extruder. A method incorporates the steps of introducing a polycarbonate oligomer, an activated carbonate, and a transesterification catalyst to the extruder through a feed section. The extruder has a feed section, a polycarbonate exit section, and a reaction section between the feed section and the polycarbonate exit section. The reaction section has one or more devolatilization units, wherein each devolatilization unit incorporates an array of vent-conveying sections and conveying sections arranged in a configuration of: (C V C)x(V)n, and/or (V C V)x(C)n. (V) is a vent-conveying section, (C) is a conveying section, x is 1 or more, and n is 1 or 0. The extruder screw in the vent-conveying sections and the conveying sections in each devolatilization unit have conveying elements or conveying elements and mixing elements and no elements that create a melt seal in the devolatilization unit. The method further includes the step of extruding the reaction components at a temperature in a range between 100° C. and 500° C., wherein during the extrusion of the reaction components, activated carbonate residue is removed through the vent-conveying sections.
    • 聚碳酸酯通过在反应性挤出机上的反应性挤出制备。 一种方法包括通过进料段将聚碳酸酯低聚物,活性碳酸酯和酯交换催化剂引入挤出机的步骤。 挤出机具有进料部分,聚碳酸酯出口部分和进料部分和聚碳酸酯出口部分之间的反应部分。 反应部分具有一个或多个脱挥发单元,其中每个脱挥发单元结合一排排气输送部分和输送部分排列成:(CVC)x(V)n和/或(VCV)x(C) n。 (V)是排气输送部,(C)是输送部,x为1以上,n为1或0.排气输送部中的挤出机螺杆和各脱挥发单元的输送部具有输送 元件或输送元件和混合元件,并且没有在脱挥发单元中产生熔体密封的元件。 该方法还包括在100℃和500℃之间的温度范围内挤出反应组分的步骤,其中在反应组分的挤出期间,通过排气输送段除去活性碳酸盐残余物。
    • 3. 发明授权
    • Polycarbonates and method of preparing same
    • 聚碳酸酯及其制备方法
    • US07482423B2
    • 2009-01-27
    • US11427861
    • 2006-06-30
    • Bernd JansenJan Henk KampsEdward KungPatrick Joseph McCloskeyPaul Michael Smigelski, Jr.
    • Bernd JansenJan Henk KampsEdward KungPatrick Joseph McCloskeyPaul Michael Smigelski, Jr.
    • C08G64/00C08G63/02
    • C08G64/307C08G64/04
    • Polycarbonates incorporating terminal carbonate groups derived from ester-substituted activated carbonates, for example terminal methyl salicyl carbonate (TMSC) derived from the use of BMSC as the activated carbonate in a transesterification process, have unfavorable properties with respect to color, hydrolytic stability and thermal stability, particularly when the polycarbonate containing such end groups is molded. The number of activated carbonate end groups formed during the melt transesterification formation of polycarbonate can be reduced, however, without sacrificing the benefits of using an activated diaryl carbonate, and without requiring a separate reaction or additional additives by reacting a dihydroxy compound with an activated diaryl carbonate in the presence of an esterification catalyst to produce a polycarbonate, wherein the molar ratio of activated diaryl carbonate to dihydroxy compound is less than 1 when expressed to at least three decimal places, for example 0.996 or less.
    • 由酯取代的活性碳酸酯衍生的末端碳酸酯基团的聚碳酸酯,例如在酯交换法中使用BMSC作为活性碳酸酯的末端甲基水杨酸碳酸酯(TMSC)在颜色,水解稳定性和热稳定性方面具有不利的性质 特别是当含有这种端基的聚碳酸酯被模制时。 然而,在聚碳酸酯的熔融酯交换形成期间形成的活化碳酸酯端基的数量可以降低,但不会牺牲使用活性碳酸二芳基酯的优点,并且不需要单独的反应或另外的添加剂,通过使二羟基化合物与活化的二芳基 在酯化催化剂存在下制备碳酸酯以制备聚碳酸酯,其中活化的碳酸二芳酯与二羟基化合物的摩尔比当表示至少三位小数,例如0.996或更小时小于1。
    • 4. 发明授权
    • Method of preparing ester-substituted diaryl carbonates
    • 酯取代的二芳基碳酸酯的制备方法
    • US07312352B2
    • 2007-12-25
    • US10984318
    • 2004-11-08
    • Paul William BuckleyJames SilvaDavid Dardaris
    • Paul William BuckleyJames SilvaDavid Dardaris
    • C07C69/96
    • C07C68/02C07C69/96
    • The present invention relates to an interfacial method of preparing ester-substituted diaryl carbonates. The method includes the steps of: forming a reaction mixture comprising phosgene, an ester-substituted phenol, an organic solvent, and a catalyst selected from the group consisting of a tertiary amine catalyst and a phase transfer catalyst, said reaction mixture having an organic phase and an aqueous phase, wherein said aqueous phase has a brine strength; allowing the reaction mixture to react wherein during the reaction, (i) the aqueous phase has a pH, and the pH is adjusted, if necessary, by the addition of an alkali metal hydroxide solution in amounts such that the pH is greater than or equal to 9.0 during at least some portion of the reaction, and (ii) the brine strength of the aqueous phase is adjusted, if necessary, by varying the concentration of the alkali metal hydroxide solution being added to maintain the pH such that the brine strength is between 15% and a saturated brine solution during at least some portion of the reaction: thereby forming an ester-substituted diaryl carbonate, wherein the reaction mixture is formed with less than 15% water of formulation, and wherein the brine strength is maintained at or above 15% and the pH is maintained at or above 9 for a sufficient portion of the process that the ester-substituted diaryl carbonate is formed with a conversion of at least 90% and a selectivity of at least 98%.
    • 本发明涉及制备酯取代的二芳基碳酸酯的界面方法。 该方法包括以下步骤:形成包括光气,酯取代的酚,有机溶剂和选自叔胺催化剂和相转移催化剂的催化剂的反应混合物,所述反应混合物具有有机相 和水相,其中所述水相具有盐水强度; 允许反应混合物反应,其中在反应期间,(i)水相具有pH,并且如果需要,通过加入碱金属氢氧化物溶液调节pH,使得pH大于或等于 在反应的至少一部分期间至9.0,和(ii)如果需要,通过改变加入的碱金属氢氧化物溶液的浓度来调节水相的盐水强度,以保持pH使得盐水强度为 在反应的至少一部分期间在15%和饱和盐水溶液之间,由此形成酯取代的碳酸二芳基酯,其中反应混合物由少于15%的制剂水形成,并且其中盐水强度保持在或 高于15%,并且pH保持在或大于9,足够部分的方法是形成酯取代的碳酸二芳基酯,其转化率至少为90%,选择性为至少98%。
    • 9. 发明授权
    • Methods for enhancing the efficacy of cytotoxic agents through the use of HSP90 inhibitors
    • 通过使用HSP90抑制剂来提高细胞毒性剂功效的方法
    • US07211562B2
    • 2007-05-01
    • US10415878
    • 2001-11-01
    • Neal RosenPamela Nathalie Munster
    • Neal RosenPamela Nathalie Munster
    • A61K35/00A61K41/00A61K38/00
    • A61K33/24A61K31/282A61K31/337A61K31/365A61K31/395A61K31/505A61K31/704A61K2300/00
    • The administration of cytotoxic agents followed by the administration of heat shock protein 90 inhibitors, such as ansamycins, has a synergistic effect on the growth inhibition of cells. This synergy occurs at doses of each cytotoxic agent that normally only causes minimal growth inhibition of cells. Such combination therapy thus allows one to use lower doses of cytotoxic agents to avoid or reduce their respective toxicity to patients without compromising their growth inhibitory effects. Thus, these combinations can be used for the treatment of an animal, preferably a mammal, that has a cell proliferative disorder, whether the cells have wild-type Rb or are Rb deficient or Rb negative. One such method, directed to treating cell proliferative disorders includes the step of administering a therapeutic effective amount of a cytotoxic agent followed by administering a therapeutic effective amount of a heat shock protein 90 inhibitor. The cytotoxic agent may be a microtubule-affecting agent, topoisomerase II inhibitor, a platinum complex, paclitaxel, or a paclitaxel derivative. The HSP90 inhibitor may be an ansamycin, radicicol or a synthetic compound that binds to the ATP-binding site of HSP90.
    • 细胞毒性剂的施用,然后施用热休克蛋白90抑制剂,例如安莎霉素,对细胞的生长抑制具有协同作用。 这种协同作用发生在通常仅引起细胞生长抑制最小的各细胞毒剂剂量。 因此,这样的组合疗法允许使用较低剂量的细胞毒剂以避免或降低其对患者的相应毒性而不损害其生长抑制作用。 因此,这些组合可用于治疗具有细胞增殖性疾病的动物,优选哺乳动物,细胞是否具有野生型Rb或Rb缺陷或Rb阴性。 针对治疗细胞增殖性疾病的一种这样的方法包括施用治疗有效量的细胞毒性剂的步骤,然后施用治疗有效量的热休克蛋白90抑制剂。 细胞毒性剂可以是微管影响剂,拓扑异构酶II抑制剂,铂络合物,紫杉醇或紫杉醇衍生物。 HSP90抑制剂可以是结合HSP90的ATP结合位点的安莎霉素,根霉素或合成化合物。